Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Ching Yao Yang, Ming Huei Fan, Carol H. Miao, Yi Jen Liao, Ray Hwang Yuan, Chao Lien Liu

研究成果: 雜誌貢獻文章

摘要

Yang et al. developed armed third-generation PD-L1-targeted ACR/CAR T cells utilizing a PD-1/PD-L1 immune checkpoint axis. Both engineered CAR T cells significantly improved tumor control and survival in models of PD-L1-expressed pancreatic cancers.

原文英語
頁(從 - 到)571-585
頁數15
期刊Molecular Therapy - Oncolytics
17
DOIs
出版狀態已發佈 - 六月 26 2020

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

指紋 深入研究「Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer」主題。共同形成了獨特的指紋。

  • 引用此